EA200500757A1 - Новое применение декстрансульфата - Google Patents

Новое применение декстрансульфата

Info

Publication number
EA200500757A1
EA200500757A1 EA200500757A EA200500757A EA200500757A1 EA 200500757 A1 EA200500757 A1 EA 200500757A1 EA 200500757 A EA200500757 A EA 200500757A EA 200500757 A EA200500757 A EA 200500757A EA 200500757 A1 EA200500757 A1 EA 200500757A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dextran sulfate
ibmir
medicament
patients
pharmaceutically acceptable
Prior art date
Application number
EA200500757A
Other languages
English (en)
Other versions
EA010409B1 (ru
Inventor
Бо Нильссон
Олле Корсгрен
Original Assignee
Профимед Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Профимед Аб filed Critical Профимед Аб
Publication of EA200500757A1 publication Critical patent/EA200500757A1/ru
Publication of EA010409B1 publication Critical patent/EA010409B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Настоящее изобретение относится к применению декстрансульфата или его фармацевтически приемлемого производного для изготовления лекарства для лечения немедленной воспалительной реакции, опосредованной кровью (IBMIR, instant blood-mediated inflammatory reaction). Кроме того, изобретение относится к применению декстрансульфата или его фармацевтически приемлемого производного для изготовления лекарства для лечения морфологического разрушения клеточных трансплантатов и отторжения клеточных трансплантатов, вызванных IBMIR. Данное изобретение можно применять для пациентов, страдающих диабетом 1 типа, которым в воротную вену трансплантируют островки Лангерганса свиньи. Введение декстрансульфата по изобретению подавляет и предотвращает отторжение и разрушение трансплантируемых островков и обеспечивает возможность нормогликемии у пациентов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500757A 2002-11-28 2003-11-26 Применение декстрансульфата для ингибирования немедленной воспалительной реакции, опосредованной кровью EA010409B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0203526A SE525461C3 (sv) 2002-11-28 2002-11-28 Ny användning av dextransulfat
PCT/SE2003/001830 WO2004047848A1 (en) 2002-11-28 2003-11-26 New use of dextran sulfate

Publications (2)

Publication Number Publication Date
EA200500757A1 true EA200500757A1 (ru) 2005-12-29
EA010409B1 EA010409B1 (ru) 2008-08-29

Family

ID=20289705

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500757A EA010409B1 (ru) 2002-11-28 2003-11-26 Применение декстрансульфата для ингибирования немедленной воспалительной реакции, опосредованной кровью

Country Status (26)

Country Link
US (5) US8629123B2 (ru)
EP (1) EP1567171B1 (ru)
JP (2) JP4315908B2 (ru)
KR (1) KR100828807B1 (ru)
CN (1) CN1296051C (ru)
AT (1) ATE359798T1 (ru)
AU (1) AU2003302378B2 (ru)
BR (1) BRPI0316666B8 (ru)
CA (1) CA2507595C (ru)
CY (1) CY1106739T1 (ru)
DE (1) DE60313356T2 (ru)
DK (1) DK1567171T3 (ru)
EA (1) EA010409B1 (ru)
ES (1) ES2285270T3 (ru)
HK (1) HK1087042A1 (ru)
HR (1) HRP20050439B1 (ru)
IL (1) IL168626A (ru)
IS (1) IS2405B (ru)
NO (1) NO326946B1 (ru)
NZ (1) NZ540744A (ru)
PL (1) PL216067B1 (ru)
PT (1) PT1567171E (ru)
SE (1) SE525461C3 (ru)
SI (1) SI1567171T1 (ru)
WO (1) WO2004047848A1 (ru)
ZA (1) ZA200504111B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007312880A1 (en) * 2006-10-20 2008-04-24 The Australian National University Inhibition of degradation of extracellular matrix
WO2008153962A2 (en) * 2007-06-08 2008-12-18 The Trustees Of The University Of Pennylvania Method of reducing tissue loss in pancreatic islet cell transplantation
WO2011109877A1 (en) * 2010-03-12 2011-09-15 The Australian National University Heparan sulfate replacement therapy
TR201910511T4 (tr) * 2010-07-16 2019-08-21 Tx Medic Ab Hücre terapisi.
CN102973592A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗糖尿病药物中的应用
SE537742C2 (sv) 2013-05-13 2015-10-13 Tx Medic Ab Dextransulfat för cellmobilisering
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
CA2951686C (en) * 2014-06-12 2019-05-21 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenesis in a subject
WO2015190989A1 (en) * 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
EP3678675A4 (en) * 2017-09-08 2021-07-07 TX Medic AB NEW USE OF DEXTRAN SULFATE
IL297275A (en) * 2020-04-15 2022-12-01 Tx Medic Ab Treatment of corona virus infections
SE544768C2 (en) * 2021-03-24 2022-11-08 Tx Medic Ab Combination for treatment of thromboinflammation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
TW318142B (ru) 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
CN1178070A (zh) * 1996-09-27 1998-04-08 刘春江 组织脏器移植用保存溶液·手术等时组织脏器保护溶液
CN1057192C (zh) * 1997-09-10 2000-10-11 上海长征医院 一种配制多器官保存液的方法

Also Published As

Publication number Publication date
NO20052505L (no) 2005-06-20
ZA200504111B (en) 2006-07-26
US9364499B2 (en) 2016-06-14
IS7908A (is) 2005-06-23
BR0316666A (pt) 2005-10-11
BRPI0316666B1 (pt) 2018-09-25
US8906884B2 (en) 2014-12-09
HRP20050439A2 (en) 2005-12-31
ATE359798T1 (de) 2007-05-15
HRP20050439B1 (en) 2007-11-30
BRPI0316666B8 (pt) 2021-05-25
US20160136331A1 (en) 2016-05-19
SE525461C3 (sv) 2005-03-23
JP2009167201A (ja) 2009-07-30
US8901104B2 (en) 2014-12-02
SE525461C2 (sv) 2005-02-22
CN1296051C (zh) 2007-01-24
PT1567171E (pt) 2007-07-09
WO2004047848A1 (en) 2004-06-10
NO326946B1 (no) 2009-03-16
SI1567171T1 (sl) 2007-08-31
ES2285270T3 (es) 2007-11-16
US20100113389A1 (en) 2010-05-06
PL376302A1 (en) 2005-12-27
HK1087042A1 (en) 2006-10-06
DK1567171T3 (da) 2007-07-16
AU2003302378B2 (en) 2008-02-21
IS2405B (is) 2008-09-15
IL168626A (en) 2011-06-30
CY1106739T1 (el) 2012-05-23
US20140094435A1 (en) 2014-04-03
EA010409B1 (ru) 2008-08-29
CA2507595A1 (en) 2004-06-10
SE0203526D0 (sv) 2002-11-28
EP1567171A1 (en) 2005-08-31
AU2003302378A1 (en) 2004-06-18
JP2006509057A (ja) 2006-03-16
DE60313356D1 (de) 2007-05-31
JP4315908B2 (ja) 2009-08-19
US20140093484A1 (en) 2014-04-03
US8629123B2 (en) 2014-01-14
DE60313356T2 (de) 2007-08-16
JP4972113B2 (ja) 2012-07-11
NZ540744A (en) 2007-02-23
US10307440B2 (en) 2019-06-04
KR100828807B1 (ko) 2008-05-09
CN1717240A (zh) 2006-01-04
US20060111319A1 (en) 2006-05-25
EP1567171B1 (en) 2007-04-18
SE0203526L (sv) 2004-05-29
KR20050089803A (ko) 2005-09-08
PL216067B1 (pl) 2014-02-28
CA2507595C (en) 2011-11-08

Similar Documents

Publication Publication Date Title
EA200500757A1 (ru) Новое применение декстрансульфата
Qian et al. Radioprotective effect of hydrogen in cultured cells and mice
ES2169128T3 (es) Procedimientos para el tratamiento de enfermedades utilizando celulas de sertoli y aloinjertos o xenoinjertos.
MA29346B1 (fr) Formulations pharmaceutiques gastrorésistantes à base de rifaximine
RU2009107030A (ru) Комбинированная терапия
TR200102977T2 (tr) Yeni tedavi yöntemi.
US10548942B2 (en) CXCR antagonistic peptides and uses thereof
EA200000058A1 (ru) Лечение посредством блокады cd154 при трансплантации ткани панкреатических островков
CA2364451A1 (en) Agent for treatment of arthritic disease
MX2008015392A (es) Tratamiento de enfermedades isquemicas que usan eritropoyetina.
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
Otsuka et al. Nicotinamide and 3-aminobenzamide reduce interferon-γ-induced class II MHC (HLA-DR and-DP) molecule expression on cultured human endothelial cells and fibroblasts
Lehnert et al. Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration.
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DK0883406T3 (da) Anvendelse af IL-7 til behandling af autoimmune sygdomme og især insulinafhængig diabe-tesmellitus i særdeleshed
Manasia et al. Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients.
Eldad et al. Cyclosporin A treatment failed to extend skin allograft survival in two burn patients
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
Wang et al. Mesenchymal Stem Cell Therapy for Acetaminophen-related Liver Injury: A Systematic Review and Meta-analysis of Experimental Studies In Vivo
Acchiardo et al. Ultrastructural changes in gentamicin nephrotoxicity
이기준 Limb transplantation: indications and recent results
Lee Relative potency factors derived from NOAELs for assessing cumulative risk of pesticides
RU2001120483A (ru) Способ лечения больных нейросенсорной тугоухостью в остром периоде
Reddy et al. Mycetoma of the Hand
RU2001132588A (ru) Новое применение вещества для пнс

Legal Events

Date Code Title Description
TK4A Corrections in published eurasian patents
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY